Resverlogix (FRA:RFS) Cyclically Adjusted PB Ratio: (As of Jul. 08, 2026)


FRA:RFS Resverlogix Corp FRA:RFS
39 GF Score
Price €0.05
! 4 Warning Signs
View Full Analysis

What is Resverlogix Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Resverlogix  (FRA:RFS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Resverlogix Cyclically Adjusted PB Ratio Related Terms


Resverlogix Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Resverlogix's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resverlogix Cyclically Adjusted PB Ratio Chart

Resverlogix Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Resverlogix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:RFS vs VRTX, REGN, ALNY: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Resverlogix's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resverlogix Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Resverlogix's Cyclically Adjusted PB Ratio falls into.


FRA:RFS
39GF Score
Resverlogix Corp FRA:RFS
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Resverlogix Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Resverlogix's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Resverlogix's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.247/132.2623*132.2623
=-0.247

Current CPI (Mar. 2026) = 132.2623.

Resverlogix Quarterly Data

Book Value per Share CPI Adj_Book
201604 -0.473 101.370 -0.617
201607 -0.539 101.844 -0.700
201610 -0.669 102.002 -0.867
201701 -0.806 102.318 -1.042
201704 -0.897 103.029 -1.152
201707 -0.867 103.029 -1.113
201710 -0.882 103.424 -1.128
201801 -0.368 104.056 -0.468
201804 -0.385 105.320 -0.483
201807 -0.641 106.110 -0.799
201810 -0.719 105.952 -0.898
201901 -0.702 105.557 -0.880
201904 -0.923 107.453 -1.136
201907 -0.848 108.243 -1.036
201910 -0.354 107.927 -0.434
202001 -0.320 108.085 -0.392
202004 -0.279 107.216 -0.344
202007 -0.270 108.401 -0.329
202010 -0.192 108.638 -0.234
202103 -0.140 110.298 -0.168
202106 -0.133 111.720 -0.157
202109 -0.152 112.905 -0.178
202112 -0.218 113.774 -0.253
202203 -0.222 117.646 -0.250
202206 -0.226 120.806 -0.247
202209 -0.230 120.648 -0.252
202212 -0.211 120.964 -0.231
202303 -0.223 122.702 -0.240
202306 -0.229 124.203 -0.244
202309 -0.246 125.230 -0.260
202312 -0.251 125.072 -0.265
202403 -0.245 126.258 -0.257
202406 -0.261 127.522 -0.271
202409 -0.267 127.285 -0.277
202412 -0.277 127.364 -0.288
202503 -0.283 129.181 -0.290
202506 -0.268 129.892 -0.273
202509 -0.264 130.287 -0.268
202512 -0.264 130.366 -0.268
202603 -0.247 132.262 -0.247

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Resverlogix Business Description

Other Exchanges RVXCF:USARVX:Canada
Address 4820 Richard Road SW, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
39GF Score

Get the complete analysis for FRA:RFS

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price